Healthcare -
Biotechnology - NASDAQ - IL
$ 5.225
-3.88 %
$ 40.9 M
Market Cap
-1.43
P/E
1. INTRINSIC VALUE
Balance Sheet
Pluri Inc.
| Current Assets | 31.1 M |
| Cash & Short-Term Investments | 30.2 M |
| Receivables | 646 K |
| Other Current Assets | 222 K |
| Non-Current Assets | 8.42 M |
| Long-Term Investments | 0 |
| PP&E | 7.25 M |
| Other Non-Current Assets | 1.17 M |
| Current Liabilities | 4.45 M |
| Accounts Payable | 964 K |
| Short-Term Debt | 1.12 M |
| Other Current Liabilities | 2.37 M |
| Non-Current Liabilities | 29.7 M |
| Long-Term Debt | 29.1 M |
| Other Non-Current Liabilities | 605 K |
EFFICIENCY
Earnings Waterfall
Pluri Inc.
| Revenue | 326 K |
| Cost Of Revenue | 4 K |
| Gross Profit | 322 K |
| Operating Expenses | 22.5 M |
| Operating Income | -22.2 M |
| Other Expenses | -814 K |
| Net Income | -21.3 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Pluri Inc.
| Net Income | -21.3 M |
| Depreciation & Amortization | 253 K |
| Capital Expenditures | -323 K |
| Stock-Based Compensation | 2.62 M |
| Change in Working Capital | -21 K |
| Others | 792 K |
| Free Cash Flow | -18.3 M |
Wall Street Analysts Price Targets
Pluri Inc.
Wall Street analysts predict an average 1-year price target for PLUR of $12 , with forecasts ranging from
a
low of
$12 to a high of $12 .
PLUR Lowest Price Target
Wall Street Target
12 USD
129.67%
PLUR Average Price Target
Wall Street Target
12 USD
129.67%
PLUR Highest Price Target
Wall Street Target
12 USD
129.67%
4. DIVIDEND
ANALYSIS
PLUR does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Pluri Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
4.5 M USD 1
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials
NEW YORK , May 27, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that it has signed a Letter of Intent (LOI) with Minaris Advanced Therapies, a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapies, to manufacture NurOwn® for its upcoming clinical trial. The LOI marks the beginning of a strategic collaboration between BrainStorm and Minaris to initiate the technology transfer of NurOwn® in preparation for clinical trial manufacturing at Minaris' state-of-the-art facility in Allendale, New Jersey.
prnewswire.com
- 1 month ago
Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd.
Acquisition of approximately 71% stake in Kokomodo Ltd. Acquisition uniquely combines Pluri's mass-scale cell production expertise with Kokomodo Ltd.
globenewswire.com
- 2 months ago
Pluri Announces Exclusive Collaboration Agreement with Hemafund to Enhance Ukraine's Radiation Emergency Preparedness
Strategic initiative to address Ukraine's urgent need for radiation countermeasures Hemafund's infrastructure ensures secure storage and rapid deployment of emergency treatments Collaboration may potentially generate over $100 million in value for both parties HAIFA, Israel, March 05, 2025 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today announced that it has signed an exclusive collaboration agreement with Hemafund Ltd. (“Hemafund”), a Ukrainian umbilical cord blood bank with clinical and research laboratories and facilities specializing in cell preservation and cryostorage (the “Collaboration” or the “Collaboration Agreement”).
globenewswire.com
- 4 months ago
Ever After Foods and Bühler Collaborate to Scale Cultivated Meat Production and Distribution
Food Industry Leader Teams With Ever After Foods to Accelerate Cultivated Meat Market Development Food Industry Leader Teams With Ever After Foods to Accelerate Cultivated Meat Market Development
globenewswire.com
- 5 months ago
Pluri Secures $6.5 Million Strategic Investment at Premium to Market, Enters Cacao Market Through Acquisition
HAIFA, Israel, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE:PLUR) ("Pluri" or the “Company"), a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today announced a $6.5 million strategic private investment (“the Investment”) led by global investor Alejandro Weinstein (the “Investor”), who will join Pluri's Board of Directors. Concurrently, Pluri is acquiring a 71% stake in Kokomodo Ltd. (“Kokomodo”), an AgTech company specializing in cultivated cacao production, for $4.5 million payable in the Company's Common Shares (the “Common Shares” and the “Kokomodo Transaction”, respectively). The Investment and the Kokomodo Transaction position Pluri to expand its leadership in sustainable food technologies and strengthen its strategic growth and operational capabilities.
globenewswire.com
- 5 months ago
Pluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease
HAIFA, Israel, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) ("Pluri" or the “Company"), an innovator in the development of leading cell-based technologies for various indications, congratulates Mesoblast Ltd. (“Mesoblast”) and its Chief Executive Officer, Silviu Itescu, on the U.S. Food and Drug Administration (the “FDA”) approval of the first MSC-based therapy for steroid-refractory acute graft-versus-host disease (“SR-aGVHD”). This landmark achievement marks a pivotal moment in the advancement of regenerative medicine and highlights the growing clinical and regulatory recognition of MSC therapies' transformative potential.
globenewswire.com
- 7 months ago
Pluri Inc. to Present at November 21st Virtual Investor Summit Microcap Event
HAIFA, ISRAEL / ACCESSWIRE / November 12, 2024 / Pluri Inc. (NASDAQ:PLUR), a leading biotechnology company that offers cell-based solutions for various industries. The company will be available for 1-on-1 meetings throughout the day in addition to their presentation.
accesswire.com
- 8 months ago
BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing
Memorandum of Understanding has been signed NEW YORK , Nov. 11, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that it has entered into a Memorandum of Understanding (MOU) with Pluri Inc. (NASDAQ: PLUR) through its wholly owned subsidiary ("Pluri"), an established global leader in the development and manufacturing of cell-based therapeutics, to manufacture NurOwn® for use in BrainStorm's planned Phase 3b trial in amyotrophic lateral sclerosis (ALS). This MOU enables BrainStorm to begin transfer of its manufacturing technology and start producing NurOwn at Pluri's manufacturing facility upon finalizing the binding definitive agreement.
prnewswire.com
- 8 months ago
Plurilock Corporate Update for Shareholders
CEO Ian L. Paterson will host a webinar and Q&A Tuesday July 23, 2024, at 1pm ET / 10am PT Announced over $20 million of new business since the beginning of the year Growth in Critical Services business driving margin expansion Oversubscribed $5.5 million financing, warrant exercises, debt conversion fortifies balance sheet Attracting top industry talent for next phase of growth Vancouver, British Columbia--(Newsfile Corp. - July 23, 2024) - Purilock Security Inc. (TSXV: PLUR) (OTCQB: PLCKF) ("Plurilock" or the "Company"), a global cybersecurity services and solutions provider, announces a corporate update. Plurilock Corporate Update Webinar Plurilock Security CEO Ian L.
newsfilecorp.com
- 1 year ago
Pluri's CDMO Selected to Manufacture Kadimastem's Novel Cell Therapy Product Candidates
PluriCDMO™, the Company's contract development and manufacturing organization, recognized as a leading manufacturing partner offering scalability and mass scale production to a growing number of innovative life science companies PluriCDMO™, the Company's contract development and manufacturing organization, recognized as a leading manufacturing partner offering scalability and mass scale production to a growing number of innovative life science companies
globenewswire.com
- 1 year ago
Pluri Subsidiary Ever After Foods Secured $10 Million Strategic Investment to Solve Cultivated Food Scalability Challenges
HAIFA, Israel, June 18, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology company Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), which transforms cells into solutions that promote global wellbeing and sustainability, today announced strategic investments in Pluri's subsidiary, Ever After Foods Ltd. (“Ever After Foods”), which offers a cutting-edge technology platform to produce cultivated food with unmatched, cost-efficient scalability. Ever After Foods is Pluri's majority-owned joint venture with Israeli food giant Tnuva Food-Tech Incubator (2019), L.P. (“Tnuva”), and has exclusive licensing rights to use Pluri's technology and intellectual property to develop, manufacture and commercialize cultivated meat. The $10 million funding round will propel Ever After Foods' cost-advantageous and scalable technology platform, positioning it as a leading technology enabler.
globenewswire.com
- 1 year ago
U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri's PLX-R18 Acute Radiation Syndrome Contract
HAIFA, Israel, June 06, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company), a leading biotechnology company that transforms cells into solutions, today announced the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has exercised its option for year two of the three-year $4.2 million contract it entered into with Pluri in July 2023. During the 12 months from July 1, 2024 through June 30, 2025, the NIAID will provide $1.4 million for the Company to manufacture the PLX-R18 cell therapy and to conduct both in vitro and in vivo studies to develop PLX-R18 as a potential novel treatment for hematopoietic complications of the acute radiation syndrome (H-ARS).
globenewswire.com
- 1 year ago
8. Profile
Summary
Pluri Inc. PLUR
COUNTRY
IL
INDUSTRY
Biotechnology
MARKET CAP
$ 40.9 M
Dividend Yield
0.00%
Description
Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
Contact
Building No. 5, Haifa, 3508409
https://pluri-biotech.com
IPO
Date
June 30, 2003
Employees
106
Officers
Mr. Lior Raviv
Chief Technology Officer
Mr. Nimrod Bar Zvi
Chief Commercial Officer
Ms. Efrat Livne-Hadass
Chief Wellbeing Officer
Mr. Yaacov Yanay
President, Chief Executive Officer & Director
Ms. Liat Zalts
Chief Financial Officer & Treasurer
Ms. Efrat Kaduri
Chief Business Development Officer of Pharma
Dr. Arthur Machlenkin Ph.D.
Chief Scientific Officer
Ms. Orly Amiran
Chief Quality Officer